Actively Recruiting
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Led by Oman Ministry of Health · Updated on 2026-03-24
38
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.
CONDITIONS
Official Title
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
o age equal to or more than13 years.
- All genders.
- All patients undergoing chronic Peritoneal Dialysis.
- Urine output equal or more than 150 ml/24 hours.
You will not qualify if you...
-
o Age less than 13 years
- Patients with type I diabetes mellitus.
- Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D).
- Patients with urine output less than 150 ml/24hours.
- Patients with recurrent hypoglycemic episodes
- Patients with acute or chronic liver disease,
- Patients who refuse to participate in the study.
- peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jehad Badawi AL LAHAM
Nizwa, Oman
Actively Recruiting
Research Team
J
Jehad Badawi B AL LAHAM
CONTACT
J
Jehad Badawi B AL LAHAM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here